Autolus Therapeutics
↗London, United Kingdom
Autolus Therapeutics plc is an early commercial biopharmaceutical company that develops, manufactures, and commercializes next-generation T cell therapies for the treatment of cancer and autoimmune diseases. The company was founded in 2014 as a spinout from the University College London (UCL) Cancer Institute, leveraging pioneering cell programming technology developed by Dr. Martin Pule. Using a broad suite of proprietary and modular T cell programming technologies, Autolus engineers precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms, and eliminate these cells. The company combines the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient's T cells to recognize and kill their cancer cells.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$0-$50M
Founded:2014
Ownership:public
Status:operating
FUNDING
Stage:Commercial Stage
Total Raised:$1200M+
Investors:Syncona Ltd, Woodford Investment Management, Perceptive Bioscience Investments, Cormorant Asset Management, Nextech Invest, Arix Bioscience, BioNTech
STOCK
Exchange:NASDAQ
Ticker:AUTL
Market Cap:$530M
PIPELINE
Stage:Commercial + Phase 1/2
Lead Drug Stage:FDA Approved
Modalities:CAR-T cell therapy, Cell therapy
Active Trials:5
Trial Phases:Phase 1: 3 | Phase 2: 1
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:BioNTech: Strategic CAR-T cell therapy collaboration with manufacturing, licensing, and co-commercialization options, University College London: Academic partnership and source of founding technology
COMPETITION
Position:Challenger
Competitors:Novartis (Kymriah - CAR-T), Gilead Sciences (Tecartus - CAR-T), Bluebird Bio, Cellectis, Carsgen Therapeutics, Kyverna Therapeutics, Takara Bio, Bristol Myers Squibb
LEADERSHIP
Key Executives:
Dr. Christian Martin Itin (Chris Itin) - Chief Executive Officer
Dr. Chris Williams - Chief Business Officer
Vesna Cizej - SVP Strategic Development
Dilip Patel - Senior Vice President, Global Pricing and Market Access
David Brochu - Senior Vice President, Head of Product Delivery
Vishal Mehta - Vice President, Head of Clinical Operations
Scientific Founders:Dr. Martin Pule (Senior Vice President, Founder & Chief Scientific Officer)
Board Members:Michael Bonney (Chair), Joseph Anderson, Robert Azelby, Linda Bain, John Berriman, Cynthia Butitta, Robert Iannone, Elisabeth Leiderman, Martin Murphy, Ravi Rao, William Young
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Autolus Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.